Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis

Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis

Saved in:

Bibliographic Details
Main Authors:	Ao Liu, Xiaoming Wang, Lian Wang, Han Zhuang, Liubo Xiong, Xiao Gan, Qian Wang, Guanyu Tao
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Series:	BMC Cancer
Online Access:	https://doi.org/10.1186/s12885-025-13577-3
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Evaluation of EGFR-TKIs and ICIs treatment stratification in non-small cell lung cancer using an encrypted multidimensional radiomics approach
by: Xingping Zhang, et al.
Published: (2025-01-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs.
by: Pakorn Prakaikietikul, et al.
Published: (2025-01-01)

Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
by: Anakha D. Rajeeve, et al.
Published: (2025-01-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
by: Chang Dong Yeo, et al.
Published: (2025-01-01)

Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
by: Song Dong, PhD, et al.
Published: (2025-01-01)

Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
by: Margaret Stalker, MD, et al.
Published: (2025-01-01)

Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY
by: Jill Feldman, MA, et al.
Published: (2025-03-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01)

EGFR Amplification and Glioblastoma Stem-Like Cells
by: Katrin Liffers, et al.
Published: (2015-01-01)

Discovery of potent allosteric antibodies inhibiting EGFR
by: Léxane Fournier, et al.
Published: (2024-12-01)

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms
by: Arianna Marinello, MD, et al.
Published: (2025-03-01)

The potential of MRI radiomics based on extrapulmonary metastases in predicting EGFR mutations: a systematic review and meta-analysis
by: Linyong Wu, et al.
Published: (2025-01-01)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
by: Álvaro Taus, et al.
Published: (2012-01-01)

A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer
by: Yinsheng Wang, et al.
Published: (2014-01-01)

Case report: A case report and literature review on the efficacy of high-dose aumolertinib combined intrathecal pemetrexed by Ommaya reservoir for EGFR-mutated NSCLC with leptomeningeal metastasis as the initial symptoms
by: Maoxi Zhong, et al.
Published: (2025-01-01)

Egfr Amplification Specific Gene Expression in Phyllodes Tumours of the Breast
by: Konstantin Agelopoulos, et al.
Published: (2007-01-01)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling
by: Xindong Wei, et al.
Published: (2025-01-01)

Quercetin alleviates endothelial dysfunction in preeclampsia by inhibiting ferroptosis and inflammation through EGFR binding
by: Meiting Shi, et al.
Published: (2025-01-01)

Baicalein inhibits PRRSV through direct binding, targeting EGFR, and enhancing immune response
by: Jing Wu, et al.
Published: (2025-01-01)

Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry
by: Michael J. Greig, et al.
Published: (2015-01-01)

Impact of the crosstalk between the PTEN and PAFR as well as PAFR and EGFR pathways in cancer
by: Anita Thyagarajan, et al.
Published: (2025-01-01)

EGFR as a biomarker of smoking status and survival in oropharyngeal squamous cell carcinoma
by: Shanmugappiriya Sivarajah, et al.
Published: (2019-01-01)

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer
by: Pietro Paolo Vitiello, et al.
Published: (2025-02-01)

EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration
by: Alexandra Collin de l'Hortet, et al.
Published: (2012-01-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
by: Jihene Elloumi-Mseddi, et al.
Published: (2013-01-01)

EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer
by: Yongbin Zheng, et al.
Published: (2025-02-01)

Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case
by: Huiyun Lv, et al.
Published: (2025-02-01)

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
by: Huiling Su, et al.
Published: (2025-02-01)

Small cell conversion complicated with hypertrophic pulmonary osteoarthropathy after targeted therapy for advanced EGFR-mutated lung adenocarcinoma: A case report
by: Sijia Zhang, et al.
Published: (2023-03-01)

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive <i>EGFR</i> and <i>KRAS</i> Mutations
by: Abhimanyu Tushir, et al.
Published: (2025-01-01)

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways
by: Li Gong, et al.
Published: (2024-12-01)

Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors
by: Eleonora De Luca, et al.
Published: (2024-01-01)

Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics
by: Lorraine Gaenaelle Gé, et al.
Published: (2025-01-01)

EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives
by: Antonio Rossi, et al.
Published: (2022-12-01)

Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
by: Yuji Uehara, MD, et al.
Published: (2025-03-01)

Epigenomic exploration of disease status of EGFR‐mutated non‐small cell lung cancer using plasma cell‐free DNA hydroxymethylomes
by: Yong Peng, et al.
Published: (2025-01-01)